Mostrar el registro sencillo del ítem
Efectividad y seguridad de la braquiterapia ocular, experiencia del Instituto Nacional de Cancerología, años 2010 a 2018
dc.contributor.advisor | José, Esguerra | |
dc.contributor.author | Gonzalez Álvarez, Iván Darío | |
dc.contributor.other | Jimenez, Adriana | |
dc.contributor.other | Esguerra, José | |
dc.contributor.other | Rojas, Fernando | |
dc.contributor.other | Camargo, Jennifer | |
dc.contributor.other | Morals, Laura | |
dc.coverage.spatial | Instituto Nacional de Cancerología - Colombia | spa |
dc.coverage.temporal | 2018 - 2020 | spa |
dc.date.accessioned | 2021-02-22T16:16:11Z | |
dc.date.available | 2021-02-22T16:16:11Z | |
dc.date.issued | 2021-01-25 | |
dc.identifier.uri | http://hdl.handle.net/10654/37414 | |
dc.description.abstract | Los tumores primarios oculares más frecuentes en la población adulta y pediátrica son el melanoma y el retinoblastoma, respectivamente. El tratamiento de estas patologías es un reto para el médico tratante, ya que debe balancear la necesidad de control de la enfermedad, frente a la conservación del órgano y su función, especialmente en el escenario de enfermedad localizada. Lo anterior, por lo general se logra mediante la combinación de terapias de control local y se prefiere sobre la enucleación. Desde su implementación, la braquiterapia ocular se ha consolidado como una alternativa terapéutica que alcanza un adecuado control local, a la vez que permite la conservación del globo ocular y preserva la visión. Con este estudio se busca describir la efectividad y seguridad de la braquiterapia ocular, en una serie consecutiva de pacientes, tratados en nuestra institución. | spa |
dc.description.tableofcontents | Resumen del manuscrito Introducción Materiales y métodos Resultados Discusión Conflicto de intereses Fuentes de financiación Referencias | spa |
dc.format.mimetype | applicaction/pdf | spa |
dc.language.iso | spa | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Efectividad y seguridad de la braquiterapia ocular, experiencia del Instituto Nacional de Cancerología, años 2010 a 2018 | spa |
dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
dc.type.local | Tesis/Trabajo de grado - Monografía - Especialización | spa |
dc.description.abstractenglish | The most common primary ocular tumors in the adult and pediatric population are melanoma and retinoblastoma, respectively. The treatment of these pathologies is a challenge for the treating physician, since he must balance the need to control the disease, against the preservation of the organ and its function, especially in the setting of localized disease. This is generally accomplished by combining local control therapies and is preferred over enucleation. Since its implementation, ocular brachytherapy has established itself as a therapeutic alternative that achieves adequate local control, while allowing the preservation of the eyeball and preserving vision. This study seeks to describe the effectiveness and safety of ocular brachytherapy in a consecutive series of patients treated at our institution. | spa |
dc.title.translated | Effectiveness and safety of ocular brachytherapy, experience of Instituto Nacional de Cancerología, years 2010 to 2018 | spa |
dc.subject.keywords | Ocular brachytherapy | spa |
dc.subject.keywords | Plaque radiotherapy | spa |
dc.subject.keywords | Retinoblastoma | spa |
dc.subject.keywords | Ocular melanoma | spa |
dc.subject.keywords | Survival | spa |
dc.subject.keywords | Local control | spa |
dc.publisher.program | Oncología Radioterápica | spa |
dc.creator.degreename | Especialista en Oncología Radioterápica | spa |
dc.subject.decs | Oncología | spa |
dc.subject.decs | Radioterapia | spa |
dc.subject.decs | Radiocirugia | spa |
dc.subject.decs | Braquiterapia | spa |
dc.contributor.corporatename | Instituto Nacional de Cancerología - Colombia | spa |
dc.description.degreelevel | Especialización | spa |
dc.publisher.faculty | Facultad de Medicina | spa |
dc.type.driver | info:eu-repo/semantics/bachelorThesis | spa |
dc.rights.creativecommons | Attribution-NonCommercial-NoDerivatives 4.0 International | spa |
dc.relation.references | 1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer Eye. 2017;31,241–57 | spa |
dc.relation.references | 2. Singh AD, Turell ME, Topham AK, Uveal Melanoma: Trends in Incidence, Ophthalmology. 2011;118(9):1881-5. | spa |
dc.relation.references | 3. Raksha R, Santosh GH. Retinoblastoma. Indian J Pediatr 2017; 84(12):937–944 | spa |
dc.relation.references | 4. Aerts I, Lumbroso-Le Rouic L, Gauthier-Villars M, Brisse H, Doz F, Desjardins L. Retinoblastoma. Orphanet Journal of Rare Diseases. 2006; 1:31, 1- 11 | spa |
dc.relation.references | 5. Moore R, Choroidal sarcoma treated by the intraocular insertion of radon seeds. Br J Ophthalmol.1930;14:145-56 | spa |
dc.relation.references | 6. American Brachytherapy Society - Ophthalmic Oncology Task Force. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1-14. | spa |
dc.relation.references | 7. Francis JH, Barker CA, Wolden SL, et al.: Salvage/adjuvant brachytherapy after ophthalmic artery chemosurgery for intraocular retinoblastoma. Int J Radiat Oncol Biol Phys. 2013; 87(3): 517–23 | spa |
dc.relation.references | 8. Brewington BY, Shao YF, Davidorf FH, Cebulla CM, Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions, Clinical Ophthalmology 2018:12, 925–34 | spa |
dc.relation.references | 9. Jampol LM, Moy CS, Murray TG, et al. The COMS Randomized Trial of Iodine 125 Brachytherapy for Choroidal Melanoma: V. Twelve-Year Mortality Rates and Prognostic Factors: COMS Report No. 28. Arch Ophthalmol. 2006;124(12):1684–93 | spa |
dc.relation.references | 10. Melia BM, Abramson DH, Albert DM, et al. Collaborative Ocular Melanoma Study Group. Collaborative ocular melanoma study (COMS) 25 randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001 Feb;108(2):348-66. | spa |
dc.relation.references | 11. Messer JA, Zuhour RJ, Haque W. Eye plaque brachytherapy versus enucleation for ocular melanoma: an analysis from the National Cancer Database. J Contemp Brachytherapy 2020; 12, 4: 303–10 | spa |
dc.relation.references | 12. Ancona-Lezama D, Dalvin LA, Shields CL. Modern treatment of retinoblastoma: A 2020 review. Indian J Ophthalmol 2020;68:2356-65 | spa |
dc.relation.references | 13. Shields CL, Shields JA, Minelli S, De Potter P, Hernandez C, Cater J, Brady L, Regression of Retinoblastoma After Plaque Radiotherapy. American Journal of Ophthalmology, 1993.115(2),181–7. | spa |
dc.relation.references | 14. Shields CL, Naseripour M, Cater J, Shields JA, Demirci H, Youseff A, Freire J. Plaque radiotherapy for large posterior uveal melanomas (≥8-mm thick) in 354 consecutive patients Ophthalmology, 2002.109(10),1838-49. | spa |
dc.relation.references | 15. Wen JC, Oliver SC, McCannel TA. Ocular complications following I-125 brachytherapy for choroidal melanoma. Eye, 2009. 23,1254–68 | spa |
dc.relation.references | 16. Read W, Crump RT, Weis E. Journal of Medical Imaging and Radiation Sciences. 2016, 47.349-55 | spa |
dc.subject.proposal | Braquiterapia ocular | spa |
dc.subject.proposal | Radioterapia de placa | spa |
dc.subject.proposal | Retinoblastoma | spa |
dc.subject.proposal | Melanoma ocular | spa |
dc.subject.proposal | Supervivencia | spa |
dc.subject.proposal | Control local | spa |
dc.publisher.grantor | Universidad Militar Nueva Granada | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_7a1f | * |
dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
dc.identifier.instname | instname:Universidad Militar Nueva Granada | spa |
dc.identifier.reponame | reponame:Repositorio Institucional Universidad Militar Nueva Granada | spa |
dc.identifier.repourl | repourl:https://repository.unimilitar.edu.co | spa |
dc.rights.local | Acceso abierto | spa |
dc.coverage.sede | Medicina | spa |
dc.rights.coar | http://purl.org/coar/access_right/c_abf2 |